Hermetica Superfood Encyclopedia
The Short Answer
EPA (eicosapentaenoic acid) from Nannochloropsis is a long-chain omega-3 polyunsaturated fatty acid that exerts anti-inflammatory effects primarily by competing with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, reducing pro-inflammatory eicosanoid synthesis and serving as a substrate for the production of anti-inflammatory resolvins and protectins. Clinical evidence for EPA from omega-3 concentrates, including algal sources, demonstrates reductions in serum triglycerides of 20–30% at doses of 2–4 g/day and modest cardiovascular risk reduction in high-risk populations.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordalgal EPA benefits
Algal EPA — botanical close-up
Health Benefits
**Triglyceride Reduction**
EPA suppresses hepatic VLDL-triglyceride secretion by inhibiting diacylglycerol acyltransferase and activating PPAR-alpha, with clinical studies of EPA-rich preparations showing 20–30% triglyceride lowering at 2–4 g/day in hypertriglyceridemic individuals.
**Anti-Inflammatory Action**
EPA competes with arachidonic acid at cyclooxygenase-1/2 and 5-lipoxygenase sites, reducing synthesis of pro-inflammatory prostaglandin E2 and leukotriene B4 while promoting production of less potent EPA-derived eicosanoids and specialized pro-resolving mediators including E-series resolvins.
**Cardiovascular Protection**
At pharmacological doses, pure EPA supplementation (as icosapentaenoic acid ethyl ester, 4 g/day) reduced major adverse cardiovascular events by 25% in the REDUCE-IT trial among statin-treated patients with elevated triglycerides, establishing mechanistic plausibility for algal EPA formulations in this indication.
**Neurological Support**
EPA is incorporated into neuronal membrane phospholipids, modulating membrane fluidity and signal transduction; meta-analyses of omega-3 supplementation suggest EPA-dominant formulations may reduce depressive symptom severity, with effect sizes in the moderate range (standardized mean difference approximately −0.5).
**Metabolic Health**
EPA activates PPAR-gamma and PPAR-alpha nuclear receptors, improving insulin sensitivity markers and reducing hepatic lipogenesis in preclinical models; epidemiological data associate higher circulating EPA levels with lower fasting insulin and reduced non-alcoholic fatty liver disease risk.
**Immune Modulation**
EPA-derived resolvins (particularly resolvin E1) bind ChemR23 and BLT1 receptors on immune cells, actively resolving inflammatory responses by limiting neutrophil infiltration and promoting macrophage efferocytosis without immunosuppression.
**Sustainable Vegan Omega-3 Source**
Nannochloropsis-derived EPA provides a complete long-chain omega-3 without reliance on fish stocks, eliminating exposure to marine contaminants such as methylmercury and PCBs, making it appropriate for vegan, vegetarian, and allergy-sensitive populations.
Origin & History
Natural habitat
Nannochloropsis is a genus of marine and brackish-water microalgae distributed globally across coastal and open-ocean environments, with commercially cultivated strains including N. oceanica, N. gaditana, and N. salina grown in photobioreactors or open raceway ponds. Optimal EPA accumulation occurs under cooler cultivation temperatures (15–19°C) and moderate salinity (approximately 3.0% w/v), conditions that trigger upregulation of desaturase and elongase enzymes responsible for EPA biosynthesis. Industrial cultivation systems now produce biomass yielding 2.5–6% EPA by dry matter, making Nannochloropsis one of the most EPA-dense microalgae available as a sustainable, fish-free omega-3 source.
“Nannochloropsis microalgae have no documented history of traditional human medicinal use, as their systematic study and cultivation are entirely modern phenomena arising from aquaculture and biofuel research beginning in the 1970s and 1980s. The genus was first formally characterized in the scientific literature by Hibberd in 1981, and its extraordinary EPA content was recognized as aquaculturally significant because Nannochloropsis biomass serves as a foundational food source for marine zooplankton and larval fish in hatcheries, effectively positioning microalgae as the origin point of ocean-based omega-3 food chains. Interest in Nannochloropsis as a direct human nutritional ingredient emerged in the context of late 20th-century sustainability concerns about global fish stock depletion and the recognition that fish accumulate EPA not through endogenous synthesis but through consumption of microalgae, establishing the rationale for 'going direct to the source.' Commercial algal EPA products targeting human supplementation markets represent an early 21st-century development, reflecting broader trends toward plant-based and vegan functional nutrition rather than any historical therapeutic tradition.”Traditional Medicine
Scientific Research
The broader clinical evidence base for EPA is robust at the compound level, with hundreds of randomized controlled trials and multiple systematic reviews assessing omega-3 fatty acids including EPA in cardiovascular, metabolic, and neurological outcomes; however, clinical trials specifically using Nannochloropsis-derived EPA as an isolated intervention are extremely limited, with most research concentrated on cultivation optimization rather than human efficacy. The landmark REDUCE-IT trial (n=8,179) demonstrated that 4 g/day of icosapentaenoic acid ethyl ester (pure EPA) reduced major adverse cardiovascular events by 25% (HR 0.75, 95% CI 0.68–0.83) in statin-treated patients with elevated triglycerides, and while this used a pharmaceutical-grade fish-derived EPA, it establishes the compound's cardiovascular potential. Algal omega-3 bioequivalence studies, primarily examining DHA-rich algal oils, suggest that microalgae-derived omega-3 fatty acids achieve comparable plasma enrichment to fish oil when matched for EPA/DHA content, but Nannochloropsis-specific bioavailability data in humans remain sparse. Preclinical studies confirm that EPA extracted from Nannochloropsis biomass is structurally identical to fish-derived EPA and possesses equivalent in vitro anti-inflammatory activity, supporting pharmacological interchangeability, though independent replication in powered human trials is needed.
Preparation & Dosage
Traditional preparation
**Algal Oil Softgels**
300–500 mg EPA per capsule; typical metabolic health doses range from 1–4 g EPA/day taken with food to maximize fat-soluble absorption
The most common commercial form; look for products standardized to at least .
**Algal Oil Liquid**
Bulk liquid forms allow flexible dosing; store refrigerated and away from light to prevent lipid oxidation; recommended to consume within 60–90 days of opening.
**Concentrated EPA Ethyl Ester (Pharmaceutical Analogue)**
4 g/day represent the clinically validated dosing model for cardiovascular endpoints and serve as the reference dose benchmark
While not Nannochloropsis-specific, pharmaceutical-grade pure EPA preparations at .
**Whole Biomass Powder**
1 g EPA dose would require approximately 17–40 g of dry biomass, making this form impractical for therapeutic EPA delivery but useful as a food ingredient
Nannochloropsis biomass in dried powder form contains 2.5–6% EPA by dry weight; achieving a .
**Timing**
EPA supplements are best absorbed when taken with the largest fat-containing meal of the day, which stimulates bile secretion and optimizes micellar solubilization; splitting doses (e.g., twice daily) may reduce GI side effects at higher doses.
**Standardization**
Reputable products should specify EPA content in milligrams per serving, state the form (triglyceride, ethyl ester, or phospholipid), and carry third-party oxidation testing (TOTOX value below 26) to confirm lipid quality.
Nutritional Profile
Nannochloropsis biomass on a dry-weight basis averages approximately 37.6% available carbohydrates, 28.8% crude protein (containing all essential amino acids), and 18.4% total lipids, with EPA constituting 19–28% of total fatty acids and 2.5–6% of total dry matter. The lipid fraction includes palmitic acid (C16:0) and palmitoleic acid (C16:1) as the dominant saturated and monounsaturated fatty acids respectively, alongside EPA as the principal polyunsaturated fatty acid; DHA content is typically negligible in Nannochloropsis compared to DHA-rich genera such as Schizochytrium. Micronutrients present include carotenoids (particularly violaxanthin and zeaxanthin serving as accessory photosynthetic pigments), chlorophyll-a, tocopherols (vitamin E homologues with antioxidant function), and a range of B vitamins including B12 in some strains, though B12 bioavailability from algal sources remains debated. EPA bioavailability from algal oil is enhanced by the phospholipid and glycolipid carrier forms present in the native biomass, and co-ingestion with dietary fat increases micellar solubilization and lymphatic absorption of this fat-soluble nutrient.
How It Works
Mechanism of Action
EPA is a 20-carbon, five double-bond omega-3 fatty acid that is incorporated into cell membrane phospholipids, where it displaces arachidonic acid and alters the substrate pool available to cyclooxygenase (COX-1/2) and lipoxygenase (5-LOX, 15-LOX) enzymes, shifting eicosanoid production from strongly pro-inflammatory series-2 prostaglandins and series-4 leukotrienes toward weakly inflammatory series-3 and series-5 counterparts. EPA also serves as a precursor to E-series resolvins (RvE1, RvE2) and protectins, specialized pro-resolving mediators that actively terminate inflammatory cascades by binding GPCRs including ChemR23, BLT1, and GPR32 on leukocytes and epithelial cells. At the transcriptional level, EPA activates peroxisome proliferator-activated receptors alpha and gamma (PPAR-α, PPAR-γ), reducing expression of NF-κB target genes encoding TNF-α, IL-6, and IL-1β, while simultaneously upregulating fatty acid oxidation genes in hepatocytes to reduce triglyceride synthesis. In Nannochloropsis biomass, EPA is predominantly esterified into glycolipids (monogalactosyldiacylglycerol, digalactosyldiacylglycerol) and phospholipids, lipid classes that may confer enhanced bioavailability compared to triglyceride-form EPA due to their polar headgroups facilitating intestinal micelle incorporation.
Clinical Evidence
Clinical evidence for EPA as a compound is strong, particularly for triglyceride reduction (20–30% at 2–4 g/day across multiple RCTs) and cardiovascular risk reduction in high-risk populations (REDUCE-IT, JELIS trials), but this evidence derives almost entirely from fish-derived or synthetically purified EPA rather than Nannochloropsis-specific preparations. Algal oil clinical trials to date have predominantly examined DHA-rich products (e.g., life'sDHA) in pregnancy and infant development, leaving a meaningful evidence gap for high-EPA algal products in metabolic and cardiovascular endpoints. One crossover bioavailability study demonstrated that algae-derived omega-3 oils produced equivalent increases in erythrocyte EPA and DHA compared to fish oil when adjusted for dose, supporting the principle of source-agnostic bioequivalence, though Nannochloropsis-specific preparations were not the subject of that study. The overall confidence in translating fish-oil EPA evidence to algal EPA is moderate-to-high based on biochemical equivalence, but confirmation through dedicated Nannochloropsis extract RCTs in metabolic health populations is required to close this evidence gap.
Safety & Interactions
EPA from algal sources at typical supplemental doses (1–4 g/day) is generally well tolerated; the most commonly reported adverse effects are gastrointestinal in nature, including fishy aftertaste (less pronounced with algal versus fish-derived EPA), nausea, loose stools, and belching, and these can be minimized by refrigerating capsules and taking them with meals. At doses above 3 g/day, EPA exerts clinically meaningful antiplatelet effects by competitively inhibiting thromboxane A2 synthesis, which may potentiate the bleeding risk of anticoagulant and antiplatelet medications including warfarin, clopidogrel, aspirin, and novel oral anticoagulants; patients on these drugs should consult a prescribing clinician before initiating high-dose EPA supplementation. EPA may modestly lower blood pressure and could have additive hypotensive effects with antihypertensive medications; it may also slightly reduce fasting blood glucose, warranting monitoring in patients on insulin or oral hypoglycemic agents. Nannochloropsis-derived EPA products are appropriate for use in pregnancy and lactation as a vegan alternative to fish oil for supporting maternal and fetal omega-3 status, though the relative absence of DHA in Nannochloropsis means that separate DHA supplementation (e.g., from Schizochytrium-derived oil) may be warranted for gestational and infant neurodevelopmental support; the FDA has designated long-chain omega-3 fatty acids as GRAS at intakes up to 3 g/day from food and supplement sources.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Nannochloropsis spp.eicosapentaenoic acidalgal EPAmarine microalgae EPAEPA 20:5(n-3)
Frequently Asked Questions
Is algal EPA from Nannochloropsis as effective as fish oil EPA?
Biochemically, EPA derived from Nannochloropsis is structurally identical to EPA found in fish oil—both are the same 20-carbon, five double-bond omega-3 fatty acid (eicosapentaenoic acid, 20:5 n-3). Bioequivalence studies on algal omega-3 oils demonstrate comparable increases in plasma and erythrocyte EPA levels relative to fish oil when doses are matched, supporting pharmacological interchangeability; however, dedicated Nannochloropsis-specific human trials confirming this equivalence across metabolic endpoints are still limited.
What is the recommended dose of EPA from Nannochloropsis for metabolic health?
Clinical evidence for EPA's metabolic benefits—particularly triglyceride reduction of 20–30%—is established at doses of 2–4 g of EPA per day, derived primarily from fish-oil and pharmaceutical EPA trials. For Nannochloropsis-derived algal EPA supplements, the same dosing framework applies; typical products provide 300–500 mg EPA per softgel, meaning 4–8 capsules daily to reach the therapeutically relevant range, taken with the largest fat-containing meal to optimize absorption.
Why does Nannochloropsis contain more EPA than other microalgae?
Nannochloropsis species upregulate Δ5 and Δ6 desaturase enzymes more efficiently than many other microalgae genera, channeling fatty acid synthesis preferentially toward EPA rather than shorter-chain precursors or DHA. EPA accumulation is further enhanced under cooler temperatures (15–19°C) and moderate salinity (approximately 3% w/v), conditions that trigger membrane fluidity adaptations requiring increased incorporation of polyunsaturated fatty acids; under optimized conditions, EPA can represent 19–28% of total fatty acids in Nannochloropsis biomass.
Can vegans and vegetarians use Nannochloropsis EPA as an omega-3 source?
Yes—Nannochloropsis-derived EPA is entirely plant-based and free from animal products, making it one of the few direct sources of long-chain EPA suitable for vegan and vegetarian diets, which typically cannot be met by ALA conversion from flaxseed or chia (conversion efficiency to EPA is less than 10% in most individuals). Unlike fish oil, algal EPA also avoids exposure to marine contaminants including methylmercury and polychlorinated biphenyls, and it carries a significantly lower environmental footprint than wild-capture fisheries.
Are there any side effects or drug interactions with Nannochloropsis EPA supplements?
At typical doses of 1–3 g EPA/day, side effects are mild and primarily gastrointestinal, including nausea, loose stools, and burping; taking capsules refrigerated and with food substantially reduces these effects. The most clinically significant interaction is with anticoagulant and antiplatelet drugs (warfarin, clopidogrel, aspirin)—EPA inhibits thromboxane A2-mediated platelet aggregation and at doses above 3 g/day may meaningfully increase bleeding time, so patients on blood thinners should disclose EPA supplementation to their prescribing physician before starting or adjusting dose.
How does Nannochloropsis EPA specifically reduce triglycerides compared to other omega-3 sources?
Nannochloropsis EPA reduces triglycerides by suppressing hepatic VLDL-triglyceride secretion through inhibition of diacylglycerol acyltransferase and activation of PPAR-alpha, with clinical studies demonstrating 20–30% triglyceride lowering at 2–4 g/day in hypertriglyceridemic individuals. This mechanism is similar to prescription EPA drugs like icosapent ethyl, making Nannochloropsis-derived EPA particularly effective for metabolic health. Fish oil sources contain mixed omega-3 fatty acids, whereas Nannochloropsis provides concentrated EPA with minimal competing lipids, potentially offering superior triglyceride-lowering efficacy at equivalent doses.
Is Nannochloropsis EPA safe for people taking blood thinners or antiplatelet medications?
EPA from Nannochloropsis has mild anticoagulant properties due to its competition with arachidonic acid at cyclooxygenase sites, which can potentiate the effects of blood thinners like warfarin or antiplatelet drugs like aspirin. Individuals taking these medications should consult their healthcare provider before supplementing with high-dose Nannochloropsis EPA (>2 g/day) to avoid excessive bleeding risk. At lower therapeutic doses, Nannochloropsis EPA is generally considered compatible with anticoagulant therapy when monitored appropriately.
What is the anti-inflammatory mechanism of Nannochloropsis EPA, and how does it compare to other anti-inflammatory supplements?
EPA from Nannochloropsis exerts anti-inflammatory effects by competing with arachidonic acid for binding sites at cyclooxygenase-1/2 and 5-lipoxygenase enzymes, thereby reducing production of pro-inflammatory eicosanoids like prostaglandins and leukotrienes. This mechanism is distinct from plant-based anti-inflammatory compounds (curcumin, resveratrol) which work through different pathways, making Nannochloropsis EPA particularly effective for inflammatory conditions related to lipid mediator dysregulation. The direct enzymatic competition gives Nannochloropsis EPA a more direct effect on classical inflammatory cascade reduction than many botanical alternatives.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w epa-from-nannochloropsis-nannochloropsis-spp curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
